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Abstract
Background:  The Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire is a
unidimensional, disease-specific measure developed in the UK and the Netherlands. This study
describes its adaptation into other languages.
Methods: The UK English ASQOL was translated into US English; Canadian French and English;
French; German; Italian; Spanish; and Swedish (dual-panel methods). Cognitive debriefing
interviews were conducted with AS patients. Psychometric/scaling properties were assessed using
data from two Phase III studies of adalimumab. Baseline and Week-2 data were used to assess test-
retest reliability. Validity was determined by correlation of ASQOL with SF-36 and BASFI and by
discriminative ability of ASQOL based on disease severity. Item response theory (Rasch model) was
used to test ASQOL's scaling properties.
Results:  Cognitive debriefing showed the new ASQOL versions to be clear, relevant and
comprehensive. Sample sizes varied, but were sufficient for: psychometric/scaling assessment for
US English and Canadian English; psychometric but not scaling analyses for German; and preliminary
evidence of these properties for the remaining languages. Test-retest reliability and Cronbach's
alpha coefficients were high: US English (0.85, 0.85), Canadian English (0.87, 0.86), and German
(0.77, 0.79). Correlations of ASQOL with SF-36 and BASFI for US English, Canadian English, and
German measures were moderate, but ASQOL discriminated between patients based on
perceived disease severities (p < 0.01). Results were comparable for the other languages. US
English and Canadian English exhibited fit to the Rasch model (non-significant p-values: 0.54, 0.68),
confirming unidimensionality.
Conclusion:  The ASQOL was successfully translated into all eight languages. Psychometric
properties were excellent for US English, Canadian English, and German, and extremely promising
for the other languages.
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Background
Ankylosing spondylitis (AS) is a chronic rheumatic dis-
ease with a worldwide prevalence of up to 0.9% [1] and
rates as high as 2.0% reported for some ethnic groups [2].
The sacroiliac joints are affected and, to a varying degree,
the spinal column. The disease may also involve the
peripheral joints and extra-articular structures [1].
Patients commonly experience pain, morning stiffness
and disability, all which generally increase with duration
of disease [3]. Systemic features, such as anorexia and
fatigue may also occur. In late disease, some patients
develop acute anterior uveitis, cardiovascular or pulmo-
nary problems [2]. Men are more commonly affected than
women [4] and, as with other sponylarthritides, AS is
associated with positivity for the HLA-B27 gene [1].
AS typically emerges during the second or third decade of
life, with the peak age of onset in the mid-20s [4]. The
condition impacts many areas of patients' lives, with
symptomatic problems affecting mood, motivation and
ability to cope with day-to-day activities [5]. Social and
work-related problems have been reported along with
adverse effects on patients' abilities to meet their needs for
stimulation, exploration and role fulfilment [1,5,6].
Reduced self-image, self-esteem and feelings of worth
have also been reported [5]. The collective impact of AS
has a substantial influence on patients' quality of life
(QOL). As the condition emerges in early adulthood, its
effects are present for much of patients' lives.
The Ankylosing Spondylitis Quality of Life (ASQOL)
questionnaire is an AS-specific measure of QOL [5]. The
instrument was designed for monitoring patients and
evaluating treatment effects of new pharmaceutical prod-
ucts from the patients' perspectives. It adopts the needs-
based model of QOL that postulates that life gains its
quality from the ability of individuals to satisfy their own
needs [7]. The model is well-established and has been
applied successfully in the development of a large number
of disease-specific QOL instruments, several of which
have become established as the outcome instrument of
choice for clinical trials and studies [8-17].
The development methodology was based on advances in
the understanding of the conceptual and practical basis of
measurement; combining the theoretical strengths of the
needs-based QOL model with the statistical and diagnos-
tic power of the Rasch model [18]. The application of the
Rasch model ensures that the fundamental scaling proper-
ties of the instrument were assessed in addition to the tra-
ditional psychometric properties. Content was derived
directly from interviews with AS patients, and extensive
assessments have confirmed that the instrument has
excellent psychometric and scaling properties [5]. The
ASQOL has been previously reviewed by the Assessments
in AS International Working Group studies. It is the most
thoroughly studied of the AS-specific QOL instruments
available and has been successfully employed in a
number of clinical trials [19-21]. The instrument was orig-
inally developed in parallel in the United Kingdom and
the Netherlands and has subsequently been adopted for
use in Hungary [22]. The purpose of the current study was
to produce validated and reliable new language versions
for the United States (English), Canada (French and Eng-
lish), France, Germany, Italy, Spain and Sweden for use in
clinical trials with the tumour necrosis factor antagonist
adalimumab [23,24].
Methods
Patients
Patients from the United States, Canada, Germany,
France, Italy, Spain, and Sweden were eligible for study
participation if they were adults (>18 years age) with a
confirmed diagnosis of AS. Potential participants were
excluded if they reported a co-morbidity or displayed any
cognitive, psychological or physical impairment that, in
the investigators' opinions, would interfere with their par-
ticipation in the study. Patients were recruited via local
participating clinical centres. Patients participating in cog-
nitive debriefing were also recruited via advertisements or
patient support groups. All centres received approval from
independent ethics committees, and the study was con-
ducted in accordance with the ethics principles of the Dec-
laration of Helsinki. Investigators assured that the study
complied with prevailing local laws and customs. Written
informed consent was obtained from all respondents
prior to the start of their participation.
Language translation
The ASQOL was translated using the dual-panel approach
[25]. This method has been uniformly employed in the
development of new language versions of needs-based
questionnaires including the ASQOL and assumes that
the verification and acceptability of translations should
rest with people typical of future respondents [25,26].
Translation involves running two panels (a bilingual and
a lay translation panel) in each target country. Working as
a group, the bilingual panel produce an initial translation
for consideration by the lay panel. The lay panel is com-
posed of individuals of average or lower educational lev-
els, who consider the draft translation to ensure the
content is expressed in clear, everyday language. When the
instrument is required for use in another English-speaking
population, only the lay panel is required.
Cognitive debriefing interviews
Cognitive debriefing interviews were conducted with AS
patients in each country to test the acceptability, compre-
hensibility, relevance and completeness of the new trans-
lations. Participants completed the ASQOL in theHealth and Quality of Life Outcomes 2007, 5:7 http://www.hqlo.com/content/5/1/7
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presence of an interviewer and were then invited to com-
ment on the items, instructions and response format.
Assessment of psychometric and scaling properties
Data used to evaluate the psychometric properties of the
new ASQOL language versions were collected from two
24-week, randomised, placebo-controlled, double-blind,
Phase III studies involving adalimumab conducted in the
United States and Europe (Study M03-607 known as
ATLAS [23]) and in Canada (Study M03-606 [24]).
ASQOL data collected at baseline, 2 weeks, and 12 weeks
after randomisation were analyzed.
Study instruments
The ASQOL comprises 18 questions, each with a dichoto-
mous "yes/no" response format, scored "1" and "0,"
respectively. Total scores range from 0–18, with a higher
score indicating poor quality of life. The Bath Ankylosing
Spondylitis Functional Index (BASFI) [27] assesses func-
tional limitations in AS via 10 questions, each employing
a 10-cm visual analogue scale (VAS). A mean of the scores
for the 10 items provides the total BASFI score, with values
ranging from 0–10. A high BASFI score indicates greater
functional limitation. The Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) [28] uses six 10-cm VAS
scales to determine the severity of five major symptoms of
AS. A mean of the scores for the six items provides the
total BASDAI score. Again, scores range from 0–10, with a
higher score indicating greater disability. The Short Form
36 Health Survey (SF-36) [29] is a general health-status
questionnaire comprising 36 items in eight domains of
physical and mental health: physical functioning, social
functioning, role-physical, role-emotional, mental health,
vitality, pain and general health perception. Physical and
Mental Component Summary scores (PCS and MCS) are
calculated by summing domain items and transforming
summations onto a scale from "0" or "worst health" to
"100 or "best health." Patient's Global Assessment of Dis-
ease Activity VAS (termed "patient VAS" below) and a
Physician's Global Assessment of Disease Activity VAS
(termed "physician VAS" below) took the form of a hori-
zontal line marked from 0 to 100. A higher score indicated
greater rated severity.
Assessment of traditional psychometric properties
Test-retest reliability (reproducibility) was assessed by
correlating baseline and Week-2 ASQOL scores using
Spearman rank correlation coefficients. Reproducibility is
best evaluated by focusing on patients with relatively sta-
ble disease conditions over time. Therefore, patients were
excluded from these analyses if they reported significant
changes (≥ 30%) in patient or physician VAS scores. Val-
ues greater than 0.85 for rank correlation coefficients were
considered evidence of high reliability [30,31].
Internal consistency was assessed using Cronbach's alpha
coefficients, for which values greater than 0.70 were con-
sidered evidence of internal consistency [31]. Construct
validity was tested by assessing convergent and discrimi-
native validity. For convergent validity, association
between ASQOL and the SF-36 domain scales, the BASFI
and the patient and physician VAS responses was assessed
by Spearman rank correlation coefficients. Moderate cor-
relations were expected, indicating that the scales assess
different but related constructs. Discriminative validity
was assessed by testing the ability of the ASQOL to dis-
criminate between groups based on severity of illness
(physician and patient VAS scores), disease activity (BAS-
DAI) and general health status (i.e., SF-36 Question 1: In
general would you say your health is; Excellent, Very
good, Good, Fair, or Poor?).
Assessment of the scaling properties of the ASQOL
Rasch analysis was conducted to assess scale unidimen-
sionality (i.e., that items assess a single underlying con-
struct) and item hierarchical ordering (i.e., items represent
different amounts of the construct assessed). In addition,
differential item functioning or DIF was assessed to ensure
items worked in the same manner across different patient
groups and to ensure item stability, to provide additional
evidence of scale reliability. The model used was the one-
parameter logistic item response theory (IRT) model [18].
Analyses were conducted using the Rasch Unidimensional
Measurement Model (RUMM2020) software [32]. This
uses the pairwise maximum likelihood estimation proce-
dure. If data from the scale are shown to fit the model, the
property of unidimensionality is confirmed. The ade-
quacy of the fit of the ASQOL to the model was evaluated
through a total Chi-square (χ2) fit statistic. A non-statisti-
cally significant χ2 is taken as evidence of fit to the model.
The logit and person coverage of the ASQOL was exam-
ined using the item-location and person-location distri-
bution maps. This provides information on item ordering,
level of QOL assessed by individual items, and the scope
of the underlying construct covered by the scales. DIF was
assessed across age, gender and disease duration (above or
below the median) subgroups using analysis of variance
(ANOVA) models. The stability of the items over time was
evaluated by examining each item for DIF by administra-
tion. Items that exhibited DIF by administration cannot
be considered stable over time, which would call into
question the scale's reproducibility. In addition, the sta-
bility of the item logit locations was assessed over time.
Items whose logit location values were more than two
standard errors (SE) apart at Time 1 and Time 2 would be
considered statistically significantly different, and, there-
fore, item stability would not be considered present [33].Health and Quality of Life Outcomes 2007, 5:7 http://www.hqlo.com/content/5/1/7
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Sample size
Which of the specific analyses described above were
undertaken for each ASQOL language version were deter-
mined by the country sample size. Traditional statistical
analyses generally employ sample sizes of 40 or more. For
Rasch analysis, data from 50 respondents allows 99%
confidence that the item calibrations are stable within ± 1
logit [34].
Results
Translation
The translation panels (both bilingual and lay) consisted
of four to six participants each, with approximately equal
numbers of men and women. Most items in the question-
naire were capable of translation into all eight languages
without difficulty. As the emphasis was on conceptual
rather than linguistic translations, some of the translated
items took a different form from the UK original. The US
and Canadian English panels replaced colloquial UK
expressions with ones more suitable for the source culture
throughout the questionnaire.
Cognitive debriefing interviews
Interviews were conducted with 12–16 patients in each
country. The samples contained broad ranges of age (18–
82 years) and disease duration (1–52 years). The samples
were predominantly men in all countries except Spain,
where equal numbers of men and women were inter-
viewed. Based on their responses, participants found the
new language versions to be clear, unambiguous, compre-
hensive and easy to complete. Completion times ranged
from 1.5–12 minutes (mean 5.8 minutes). All language
versions were considered relevant to patients with AS in
the target countries. No changes were required to any of
the individual language versions as a result of the debrief-
ing exercise.
Assessment of psychometric and scaling properties
Participant details are shown in Table 1. Sample size var-
ied considerably by country. Those in the USA and Can-
ada (English language version) were sufficient to permit
assessment of psychometric and scaling properties. The
Germany sample was sufficient to allow traditional psy-
chometric analyses but not assessment of scaling proper-
ties. Samples for the remaining countries were relatively
small and are therefore presented as preliminary evidence
of these properties. Further studies will be required to con-
firm the properties of these language versions.
Table 2 shows scores on selected instruments at baseline.
The samples covered broad ranges of disease duration and
severity. A majority of patients viewed themselves as hav-
ing "good" or "fair" health as rated by the SF-36 general
health question. There were some differences observed
between physician and patient VAS scales, with the great-
est disparity evident between the United States and Swe-
den (possibly a result of the small sample size in the latter
country). Ceiling effects for the ASQOL in all countries
were minimal, with the highest effect in the United States
(4.7% obtained the maximum score).
Traditional Psychometric Properties
The results of the test-retest reliability and internal con-
sistency analyses are shown in Table 3. The US and Cana-
dian (English and French), French and Swedish versions
were shown to have adequate test-retest reliability. The
reliability for the Italian sample was borderline and the
German and Spanish measures showed slightly lower reli-
ability than the desired 0.85 level. However, it must be
noted that analysis carried out in countries other than the
US and Canada is only preliminary due to the sample
sizes and further investigation is needed before any firm
conclusions can be made. Cronbach's alpha coefficients
were within an acceptable range for all new language ver-
sions of the ASQOL.
Table 4 presents the association between ASQOL and
comparator instrument scores at baseline. Observed cor-
relations with the BASFI and SF-36 domains were moder-
ate for the US English, Canadian English and German
versions, providing evidence of convergent validity. As the
sample sizes for these countries were sufficiently large,
confidence can be placed in the results obtained. For the
remaining countries, the smaller sample sizes have pro-
duced potentially spurious results, and definitive conclu-
sions cannot be drawn. The ASQOL had greater
correlations with the patient VAS than physician VAS
scores in most countries. Again, this would be expected, as
both the patient VAS and the ASQOL were completed by
patients and reflected their subjective assessments of their
conditions. The ASQOL discriminated between patients'
disease activity groups as assessed by the BASDAI. The
groups with greater disease activity (above median BAS-
DAI scores) had higher mean ASQOL scores (indicating
poorer QOL). These differences were statistically signifi-
cant for the US, Canadian English, German and French
samples (Figure 1A). Figure 1B indicates that the US,
Canadian English, German and Swedish versions differ-
entiated between patients on the basis of self-rated health
by SF-36 Questions 1.
Evidence of responsiveness was provided by comparing
ASQOL scores at baseline and after 12 weeks of treatment.
Figure 2 shows that the mean ASQOL scores are higher at
Time 1 than Time 2. This difference was significant for all
language versions except the Swedish and Canadian
French versions. Again, small sample sizes may explain
why significant changes were not observed for these ver-
sions. The effect size for this change was large for Germany
(0.85) and moderate (0.53–0.77) for the other languages,H
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Table 1: Sample Details for Psychometric and Scaling Data
US (N = 148) Canadian English
(N = 66)
Canadian French
(N = 16)
French
(N = 18)
German
(N = 37)
Italian
(N = 22)
Spanish
(n = 24)
Swedish
(n = 9)
Gender Male (%) 111 (75.0) 51 (77.3) 14 (87.5) 12 (66.7) 26 (70.3) 16 (72.7) 19 (79.2) 8 (88.9)
Female (%) 37 (25.0) 15 (22.7) 2 (12.5) 6 (33.3) 11 (29.7) 6 (27.3) 5 (20.8) 1 (11.1)
Age Mean (SD) 44.7 (12.5) 39.82(10.5) 45.3 (12.0) 35.7 (8.0) 41.9 (11.8) 40.7 (10.8) 38.0 (9.0) 37.6 (9.1)
Median (IQR) 46.0
(34.0–55.0)
41.0
(32.0–45.0)
44.5
(38.3–53.8)
34.5
(30.3–42.0)
42.0
(33.0–52.5)
44.0
(34.5–49.0)
8.6
(5.7 – 17.1)
36.0
(30.5 – 45.5)
Range 18.0–71.0 18.0–69.0 28.0–69.0 25.0–55.0 23.0–62.0 21.0–58.0 3.3 – 37.4 24.0 – 52.0
Disease duration Mean (SD) 11.0 (10.3) 12.3 (7.5) 17.0 (7.5) 9.3 (8.0) 9.7 (9.1) 9.2 (9.4) 12.2 (8.9) 11.4 (9.4)
Median (IQR) 7.6
(2.4–18.3)
11.6
(5.4–18.1)
16.3
(10.3–22.6)
9.8
(4.3–13.7)
6.2
(1.9–15.4)
4.9
(1.2–18.3)
8.6
(5.7 – 17.1)
11.7
(0.5 – 19.8)
Range 0.1–48.4 0.2–40.3 5.2–30.1 0.2–17.4 0.2–35.3 0.1–28.4 3.3 – 37.4 0.1 – 25.3
IQR = interquartile Range: the distance between the 75th percentile and the 25th percentile.
Table 2: Baseline Instrument Scores by Country
US (N = 148) Canadian English
(N = 66)
Canadian French
(N = 16)
French
(N = 18)
German
(N = 37)
Italian
(N = 22)
Spanish
(N = 24)
Swedish
(N = 9)
ASQOL Mean (SD) 9.5 (4.4) 11.4 (4.4) 10.9 (3.6) 10.5 ( 3 . 9 )1 0 . 6  ( 3 . 7 )1 2 . 1  ( 4 . 5 ) 11.8 (4.1) 7.2 (3.9)
Median (IQR) 10.0
(6.0–10.0)
12.5
(8.0–15.0)
10.0
(9.3–12.8)
11.5
(9.0–13.0)
11.0
(9.0–14.0)
12.5
(8.8–16.0)
12.5
(9.0–15.0)
7.0
(3.0–10.0)
Range 1–18 0–18 2–17 2–17 2–18 3–17 3–18 3–14
% Scoring, min 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0
% Scoring, max 4.7 1.5 0.0 0.0 2.7 0.0 4.2 0.0
Patient VAS* Mean (SD) 62.8 (21.5) 68.8 (17.6) 59.8 (22.6) 51.8 (19.7) 66.0 (18.9) 69.9 (23.3) 64.2 (18.6) 45.7 (22.3)
Median (IQR) 66.0
(50.3–79.0)
69.5
(58.8–82.3)
58.0
(46.5–82.5)
46.5
(39.0–66.8)
67.0
(54.0–81.5)
78.0
(58.0–88.0)
66.0
(45.0–79.0)
38.0
(26.5–67.5)
Range 7–100 19–97 9–92 16–88 19–100 9–97 32–100 18–78
SF-36 Question 1# Excellent (%) 7 (4.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Very Good (%) 18 (12.2%) 9 (13.6%) 1 (6.3%) 0 (0) 1 (2.7%) 0 (0) 0 (0) 4 (44.4%)
Good (%) 73 (49.3%) 22 (33.3%) 3 (68.8%) 7 (38.9%) 5 (13.5%) 1 (4.5%) 3 (12.5%) 2 (22.2%)
Fair (%) 38 (25.7%) 25 (37.9%) 11 (18.8%) 8 (44.4%) 22 (59.5%) 10 (45.5%) 10 (41.7%) 1 (11.1%)
Poor (%) 11 (7.4%) 10 (15.2%) 1 (6.3%) 3 (16.7%) 9 (24.3%) 11 (50.0%) 11 (45.8%) 2 (22.2%)
*Patient VAS = Patient's Global Assessment of Disease Activity Visual Analogue Scale. #SF-36 Question 1: "In general, how would you say your health is: Excellent, Very Good, Good, Fair, or Poor?"Health and Quality of Life Outcomes 2007, 5:7 http://www.hqlo.com/content/5/1/7
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with the exception of Canadian French (0.26). This sug-
gests that the new ASQOL language versions are respon-
sive to change over time.
Scaling properties of the ASQOL
Scaling properties were assessed for the US and Canadian
English language versions of the ASQOL. Application of
Rasch analysis revealed that both versions exhibited suffi-
cient fit to the model (non-significant χ2 p-values: United
States, 0.54; Canadian English, 0.68), confirming unidi-
mensionality. The item hierarchy was similar over time
for each language version, and logit values were stable
over time. The item for both languages representing the
greatest degree of the underlying trait measured was Item
16, "I find it difficult to wash my hair." Conversely, the
item representing the lowest degree of the underlying trait
measured was Item 14, "The pain is always there." Item
stability over time was assessed by examining each item
for differential item functioning (DIF) based on adminis-
tration time point. No items in either the US or Canadian
English version exhibited significant DIF by administra-
tion (p ≤ 0.01), providing evidence of the reliability of
both. The person-item location distributions demon-
strated that the ASQOL items targeted the respondents rel-
atively well (data not shown).
DIF was also assessed according to demographic factors
(age, sex, and duration of disease. For the US data, there
was no significant DIF (p < 0.01) according to duration of
disease. However, there was uniform DIF observed for one
item each related to age and sex, respectively. Women
were significantly more likely than men to affirm the item
"I sometimes feel like crying." Those who were younger
than the median age (46 years) were significantly more
likely to affirm the item "I am tired all the time" than
those who were older than the median age. No items in
the Canadian-English ASQOL exhibited DIF by demo-
graphic factors.
Discussion
The ASQOL was successfully translated into the target lan-
guages. The cognitive debriefing interviews suggest that
the new language versions have high face and content
validity, and are clear, comprehensive and acceptable to
patients in each country.
The data available for the assessment of psychometric and
scaling properties of the new language versions were gen-
erated from a 12-week, multinational clinical trial. As
these analyses were retrospective, it was not possible to
guarantee that sufficient data were collected in each coun-
try. Consequently, small sample sizes were observed in
some countries, which precluded the completion of cer-
tain analyses for those ASQOL language versions. Test-
retest reliability was excellent for those versions with
acceptable sample sizes (US and Canadian English).
Preliminary evidence of reliability obtained for the
remaining language versions was encouraging. The inter-
nal consistency was adequate in all language versions.
Correlations between the new ASQOL language versions
and the BASFI and SF-36 scales were moderate, indicating
that they assess related but distinct concepts. Construct
validity was further assessed by examining the ASQOL's
ability to distinguish between high-scoring and low-scor-
ing groups on the comparator measures. The Canadian
English, US and German ASQOL versions were able to dis-
tinguish between groups, providing strong evidence of
their discriminative abilities. The French language version
showed promising discriminative ability while the Cana-
dian French, Swedish, Italian and Spanish language ver-
sions showed limited ability to discriminate between
groups. The lack of findings in the latter countries may be
explained by the small sample sizes available rather than
a shortcoming of the ASQOL language versions.
Further data collection and analyses are required to con-
firm the discriminative ability of the Canadian French,
Table 3: ASQOL Test-Retest Reliability and Internal Consistency Values by Country
Test-retest reliability Internal Consistency:
Cronbach's Alpha Coefficient
NC o r r e l a t i o n * N Baseline Week 12
US 102 .85 148 .85 .92
Canadian English 51 .86 66 .86 .91
Canadian French 12 .87 16 .44 .83
French 12 .96 18 .81 .93
German 28 .77 37 .79 .81
Italian 12 .84 22 .87 .93
Spanish 14 .77 24 .84 .93
Swedish 7. 8 59. 8 1 . 8 6
* Spearman rankH
e
a
l
t
h
 
a
n
d
 
Q
u
a
l
i
t
y
 
o
f
 
L
i
f
e
 
O
u
t
c
o
m
e
s
 
2
0
0
7
,
 
5
:
7
h
t
t
p
:
/
/
w
w
w
.
h
q
l
o
.
c
o
m
/
c
o
n
t
e
n
t
/
5
/
1
/
7
P
a
g
e
 
7
 
o
f
 
1
0
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 4: Correlations Between ASQOL Scores and Comparator Instruments at Baseline
N Correlation of ASQOL and SF-36 Domains Correlation of 
ASQOL and BASFI
Correlation of ASQOL 
and Physician VAS
Correlation of ASQOL 
and Patient VAS
Functioning Physical 
Health
Role- 
Emotional
Energy/
Fatigue
Emotional 
Well-being
Social 
Functioning
Pain General 
Health
USA 148 -.56* -.59* -.41* -.57* -.49* -.69* -.69* -.50* .57* .31* .61*
Canadian 
English
66 -.70* -.47* -.24 -.50* -.47* -.67* -.64* -.57* .68* .31 .36*
German 37 -.43* -.21 -.33 -.54* -.52* -.55* -.63* -.37 .52 .14 .58*
Spanish 24 -.63* -.40 -.45 -.49 -.62* -.39 -.39 -.52* .61* .43* .34
Italian 22 -.65* -.31 -.60* -.27 -.73* -.56* -.29 -.61* .66* .26 .24
French 18 -.31 -.49 -.15 -.57 -.46 -.65* -.51 -.28 .29 .45 .46
Canadian 
French
16 -.67* -.44 -.45 -.56 -.36 -.47 -.42 -.26 .64* .34 .53
Swedish 9 -.82* -.70 .13 -.83* -.84* -.54 -.90* -.55 .74 .31 .49
*Correlation is significant at the 99% level;correlation is significant at the 95% level.Health and Quality of Life Outcomes 2007, 5:7 http://www.hqlo.com/content/5/1/7
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A. Discriminative validity of the ASQOL based on BASDAI scores Figure 1
A. Discriminative validity of the ASQOL based on BASDAI scores. B. Discriminative validity based on self-rated health.
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Swedish, Italian, and Spanish ASQOL language versions.
Responsiveness to change was assessed via analysis of
change in scores over the 12-week trial period using effect
sizes and within-group statistical analyses. Analyses indi-
cated that all new versions of the ASQOL (except Cana-
dian French and Swedish) were responsive to change.
The sample sizes available for the US and Canadian Eng-
lish versions were sufficient to allow assessment of scaling
properties. Rasch analyses were performed to examine the
item stability of the questionnaires. Analyses indicated
that the hierarchy of item ordering was relatively consist-
ent over time for both these versions. In addition, the item
logit locations appeared to be relatively stable over time.
Examination of DIF showed that these language versions
of the ASQOL did not exhibit DIF by administration. The
combination of evidence from the Rasch analyses suggests
that the Canadian English and US versions of the ASQOL
have the property of item stability and are reliable assess-
ments of QOL over time.
The psychometric evaluation of the new language versions
of the ASQOL has been largely successful. Based on the
research presented here, strong claims can be made for the
reliability, validity and responsiveness of the Canadian
English and US language versions. The German and
French language versions exhibited encouraging validity
and responsiveness. Further evidence is needed of the reli-
ability and validity of the Canadian French, Swedish, Ital-
ian, and Spanish language versions because of the
relatively small sample sizes from those countries.
The authors recommend that ASQOL data continue to be
collected for all language versions, to provide further evi-
dence of their psychometric properties – particularly for
the Canadian French, French, Swedish, Italian, and Span-
ish language versions.
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Mean ASQOL scores at baseline (time 1) and 12 weeks (time 2).
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